1996
DOI: 10.1046/j.1365-2559.1996.d01-537.x
|View full text |Cite
|
Sign up to set email alerts
|

Expression of metastasis suppressor gene product, nm23 protein, is not inversely correlated with the tumour progression in human malignant melanomas

Abstract: An inverse correlation between the nm23 RNA level and tumour progression of melanocytes has been reported. To elucidate whether the expression of nm23 gene product in malignant melanoma is also inversely correlated with metastatic potential, conventional prognostic parameters or the tumour suppressor protein p53, immunohisto-chemical studies using a monoclonal antibody against nm23-H1 protein were performed on 138 benign and malignant melanocytic tumours. The expression of nm23 protein was compared with that o… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

3
12
0

Year Published

1998
1998
2004
2004

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 14 publications
(15 citation statements)
references
References 28 publications
3
12
0
Order By: Relevance
“…In that light, it is of considerable interest that all SSMMs and LMMs in this series-which were defined as radial growthphase lesions by use of morphologic guidelinesshowed statistically lower levels of immunolabeling when compared with nodular melanomas, for which the vertical growth phase is a sine qua non [28]. This observation adds to prior literature suggesting that mp53 serves a 'permissive" role in melanoma serving to "allow' a secondary, more aggressive (i.e., vertical growth-phase) clone of tumor cells to emerge [19,53,56]. On a more pedestrian but nevertheless practical level, statistical 'modeling" of our data (techniques not shown) suggests that an arbitrary immunolabeling cutoff of 10% would be effective in helping to objectify the presence of vertical growth in melanomas.…”
Section: Discussionmentioning
confidence: 68%
See 2 more Smart Citations
“…In that light, it is of considerable interest that all SSMMs and LMMs in this series-which were defined as radial growthphase lesions by use of morphologic guidelinesshowed statistically lower levels of immunolabeling when compared with nodular melanomas, for which the vertical growth phase is a sine qua non [28]. This observation adds to prior literature suggesting that mp53 serves a 'permissive" role in melanoma serving to "allow' a secondary, more aggressive (i.e., vertical growth-phase) clone of tumor cells to emerge [19,53,56]. On a more pedestrian but nevertheless practical level, statistical 'modeling" of our data (techniques not shown) suggests that an arbitrary immunolabeling cutoff of 10% would be effective in helping to objectify the presence of vertical growth in melanomas.…”
Section: Discussionmentioning
confidence: 68%
“…Among the melanomas, 31 of 32 NMMs (97%), 53 of 65 SMMs (820/o), and 14 of 23 LMMs (610/o) showed discernible labeling for this protein at levels equaling or exceeding 1 % of the neoplastic cells (respective ranges 1-53%, 1-16%, and 1-6%). In contrast, only 7 of 23 examples of MANs (30%) were mp53-immunopositive (range 1%-5%).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Moreover, nm23 protein expression appears to be reduced or lost in metastatic skin melanoma compared to primary tumors Bodey, Kaiser and Goldfarb, 1997) and in nodular melanoma compared to in situ melanoma and in Spitz nevi of the skin (Lee, Pirdas and Lee, 1996). Notably, some data suggest that there is no difference in nm23 protein levels between skin nevi and melanoma (Saitoh et al, 1996), or in nm23 mRNA between cell lines from metastatic and primary skin melanomas and in nm23 protein between nevi and metastatic skin melanoma (Easty et al, 1996). Also, a few recent studies have failed to correlate reduced or lost nm23 protein expression with adverse prognosis for patients with skin melanoma (Holmes and MacKie, 1996 ;Van den Oord et al, 1997).…”
Section: Discussionmentioning
confidence: 99%
“…Nm23-H1 codifies for the sub-unit A of the dinucleotide diphosphate (NDP) kinases involved in the synthesis of nucleoside triphosphate, not mediated by ATP (Lombardi et al 2000). In several human neoplasias, such as breast, ovarian, and hepatocellular carcinomas, a reduced expression of NM23 has been observed, together with a higher metastatic potential and a reduction in patient survival (Luo et al 1993;Nakamura et al 1998;Shaitoh et al 1996). Nevertheless, in many other tumors, such as melanomas and thyroid and gastric cancers, the role played by NM23 in metastatic ability and prognosis is still not clear (Gazzeri et al 1996;Nakamori et al 1993).…”
mentioning
confidence: 99%